ZYXI Stock UPDATES Zynex Inc (ZYXI) 0.2200 08/30/2014 15:26:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Zynex Inc (ZYXI) 0.2200 $ZYXI

Zynex Announces Brian Alleman as Chief Financial Officer
Marketwire - Mon Jul 21, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the appointment of Brian Alleman as its new chief financial officer.

Zynex Achieves Compound Pharmacy License Approval in 36 States
Marketwire - Tue Jul 15, 7:03AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it has attained compound pharmacy licensing approval in seventeen additional states bringing the total to thirty-six approvals.

Zynex Appoints Director of Business Development
Marketwire - Wed Jun 25, 7:02AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced the hiring of Steve Siefring as Director of Business Development. Mr. Seifring will be responsible for driving sales activities in the electrotherapy and compound pharmacy business, reporting to Robert Bird, Vice President of Sales in the US.

Zynex Announces 2013 Year End Results
Marketwire - Thu Mar 27, 7:02AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today its year end 2013 financial results.

Zynex Schedules Year End 2013 Earnings Conference Call and Webcast
Marketwire - Thu Mar 20, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host an investor webcast on Thursday, March 27, 2014 at 11:00 a.m. ET -- 9:00 a.m. MT -- to discuss the Company's year end 2013 results.

Zynex Non-Sterile Compound Pharmacy Attains Licensing in 19 States
Marketwire - Mon Mar 03, 7:01AM CST
Zynex, Inc. (OTCQB: ZYXI), a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that its subsidiary Zynex Medical, recently received its 19th state license for its non-sterile compound pharmacy.

Zynex Expands Electrotherapy Product Sales Channel
Marketwire - Tue Feb 11, 7:02AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnostics announces that it signed a strategic sales and marketing agreement with Total Care Marketing, LLC to sell its primary electrotherapy device, the NexWave, through Total Care Marketing's sales organization.

Zynex Receives Roszdravnadzor (Russian Equivalent of FDA) Clearance to Market Neuromove(TM) Stroke Recovery Device and NexWave(TM) Electrotherapy Device in Russia
Marketwire - Thu Feb 06, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that Russia's Federal Service on Surveillance in Healthcare (Roszdravnadzor) has granted clearance to market its NeuroMove(TM) stroke recovery device and NexWave(TM) electrotherapy device.

ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.

Zynex Appoints Vice President of Sales for NeuroDiagnostics Division
Marketwire - Tue Jan 07, 7:00AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has appointed James Carter as Vice President of Sales for its NeuroDiagnostics division.

Zynex Signs Distribution Agreement for China Market
Marketwire - Tue Dec 24, 7:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation and neurological diagnosis, announced today that it signed a five-year exclusive distribution agreement with DIH Medical Technologies Co Ltd for the distribution of its NeuroMove device in China commencing December 17, 2013. Although the agreement can be cancelled upon 60 days' notice by DIH, the minimum purchase requirements over the agreements expected five-year term would equal sales of $4.6 million. The first year's minimum commitment is $750,000.

Zynex Announces Investor Relations Initiative
Marketwire - Fri Dec 20, 8:30AM CST
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy, stroke rehabilitation, and neurological diagnosis, announced today that it has enabled Level 2 quote visibility for investors though the OTC Markets Group.

Zynex Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2013 financial results.

Zynex Schedules Second Quarter 2013 Earnings Conference Call and Webcast
Marketwire - Thu Aug 01, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today that it will host an investor webcast, Thursday, August 8, 2013 at 9:00 a.m. Mountain Time - 11:00 a.m. Eastern Time to discuss the Company's second quarter 2013 results.

Zynex Signs Strategic Agreement With Advanced Brain Monitoring, Expands Presence in Sleep Diagnostic Market
Marketwire - Mon Jul 22, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnostics and cardiac monitoring, announces that it signed a strategic sales, marketing and distribution agreement with California based Advanced Brain Monitoring.

The Neuromodulation Devices Market - Rising Numbers For Cases of Alzheimer's, Epilepsy, and Parkinson's Disease Leading to High Demand for Non-Invasive Treatments
M2 - Thu Jul 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s7pvwv/neuromodulation) has announced the addition of the "The Neuromodulation Devices Market" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.). For more information visit http://www.researchandmarkets.com/research/s7...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Zynex Updates Financial Outlook for 2013
Marketwire - Fri Jul 12, 2:25PM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced today the Company's updated financial outlook for the remainder of 2013.

Neuromodulation Market Research Report Forecasts to 2017 - Neuromodulation emerging as one of the fastest growing segments of the medical device market
M2 - Fri May 10, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfbns4/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S. Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation. The key players in the neuromodulation devices market are: - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. Scope of the Report The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario. For more information visit http://www.researchandmarkets.com/research/wf...modulation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ZYXI Q1: Revenue and Margins Impacted - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 09, 7:16AM CDT
ZYXI Q1: Revenue and Margins Impacted

Zynex Announces First Quarter 2013 Financial Results
Marketwire - Wed May 08, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its first quarter 2013 financial results.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 84

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 110

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 39

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

Constellation Brands Innovates with New Wine Portfolio Focus

Updated Category News Views 254

Constellation Brands Completes Transaction with The Wine Group ROCHESTER, N.Y. — Constellation Brands (NYSE: STZ), a prominent player in the beverage alcohol industry, has officially finalized its transaction with The Wine Group, marking a significant shift in its wine strategy. By divesting mainstream wine brands and associated assets, Constellation aims to concentrate...

Continue Reading
GomSpace North America Secures Major USD 1.5 Million Order

Updated Category News Views 198

Exciting Order Announcement from GomSpace North America GomSpace North America, a subsidiary of GomSpace Group AB, has successfully secured a major order valued at USD 1.5 million. This contract, which underscores the growing trust in GomSpace's advanced technological solutions, involves supplying key components aimed at supporting an upcoming satellite mission. Details...

Continue Reading
Venice Comprehensive Dentistry's Evolution: A New Era of Care

Updated Category News Views 169

Venice Comprehensive Dentistry's Transformation Venice Comprehensive Dentistry, previously known as Florida Dental Implant Center, has officially announced a significant rebranding aimed at better reflecting the diverse range of dental services it now offers. This exciting change marks a pivotal moment in the practice's journey, emphasizing its commitment to comprehensive...

Continue Reading
Important Insights from ABC Arbitrage's Upcoming General Meeting

Updated Category News Views 183

Understanding ABC Arbitrage's General Meeting ABC arbitrage is gearing up for a significant event as it prepares for its upcoming Combined General Meeting. Scheduled at a centrally located venue, this meeting promises to provide shareholders with essential insights into the company’s direction. Meeting Details and Important Dates The Combined General Meeting of ABC...

Continue Reading
Arrowpoint Investment Partners Selects SS&C for Fund Services

Updated Category News Views 291

Arrowpoint Investment Partners Chooses SS&C for Fund Management Arrowpoint Investment Partners, a newly established multi-strategy hedge fund investment firm, has made a significant move in the evolving financial services landscape by selecting SS&C GlobeOp for the administration of its flagship investment fund, valued at $1 billion. This decision highlights the firm’s...

Continue Reading